BioNTech SE at JPMorgan Healthcare Conference Transcript
Great. Good morning, everyone. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan and we're continuing the conference today with BioNTech.
I'm joined by the company's CEO, Dr. Ugur Sahin. He's going to give a presentation on the company and then we're going to move right into Q&A. If you have a question in the room, just raise your hand and someone will bring you a microphone or alternatively, if you want to submit questions on the portal, you can do that too, and I'll read them up here.
So with that, let me turn it over to Ugur.
Thank you, Jessica. Good morning, everyone, and welcome also on behalf of my colleague, Jens Holstein here. I wish you -- I wish everyone a happy new year, healthy, prosperous and with peace. So some statements.
So let me start with introducing slide, which is known for many of you. BioNTech was founded 15 years ago with the vision to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |